Cytek Biosciences, Inc.CTKBNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank43
3Y CAGR-82.6%
5Y CAGR-70.5%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-82.6%/yr
Quarterly compound
5Y CAGR
-70.5%/yr
Recent deceleration
Percentile
P43
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 0.07% |
| Q3 2025 | 1.47% |
| Q2 2025 | -9.24% |
| Q1 2025 | 0.02% |
| Q4 2024 | -1.61% |
| Q3 2024 | -1.19% |
| Q2 2024 | 2.09% |
| Q1 2024 | -9.87% |
| Q4 2023 | -2.70% |
| Q3 2023 | -7.95% |
| Q2 2023 | 21.68% |
| Q1 2023 | 2.33% |
| Q4 2022 | 12.68% |
| Q3 2022 | 2.54% |
| Q2 2022 | 5.12% |
| Q1 2022 | 13.41% |
| Q4 2021 | 16.42% |
| Q3 2021 | -1.87% |
| Q2 2021 | 21.59% |
| Q1 2021 | 16.17% |
| Q4 2020 | 29.89% |
| Q3 2020 | 15.78% |
| Q2 2020 | -3.32% |
| Q1 2020 | 0.00% |